SubsidieMeestersClinical validation of NANO-PL: a hydrogel-based formulation of a small molecule for a highly targeted therapy against Glioblastoma Multiforme (GBM)
NANO-PL is a hydrogel-based, one-time treatment for glioblastoma that shows promising safety and efficacy, including tumor eradication and improved survival rates in preclinical models.
Projectdetails
Introduction
Glioblastoma (GBM) is considered the highest unmet need in oncology. The average life expectancy of GBM patients is 12-18 months, and the 5-year survival rates remain below 7%. Despite the efforts, the available therapy today counts only a few (ineffective) approved therapies.
Discovery and Development
Using a machine learning algorithm, we have discovered a correlation between a small molecule and an unexplored target in GBM. We have developed a hydrogel-based formulation of the molecule with great safety and efficacy in vivo.
Efficacy Results
Our formulation showed:
- 40% long-term survival in a GBM rat model
- Complete tumour eradication after a single dose treatment
Treatment Application
NANO-PL is a one-time treatment, applied locally during surgery, which is effective even in GBM cells that are resistant to the standard of care or those involved in recurrence. NANO-PL also showed synergistic efficacy with temozolomide, the standard-of-care.
Future Prospects
The EIC will enable the clinical validation of NANO-PL, completely unlocking the GBM treatment.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 3.800.691 |
Tijdlijn
| Startdatum | 1-11-2024 |
| Einddatum | 28-2-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- TARGTEX SApenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Clinical validation of GLIX1: a small molecule that targets epigenetic changes in cancer cells to treat glioblastoma multiforme (GBM), the highest global unmet need in oncology.GLIX1, a novel therapy targeting deregulated mechanisms in GBM, shows promising tumor regression in preclinical studies and aims for clinical validation to improve patient outcomes. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Clinical validation of GLIX1: a small molecule that targets epigenetic changes in cancer cells to treat glioblastoma multiforme (GBM), the highest global unmet need in oncology.
GLIX1, a novel therapy targeting deregulated mechanisms in GBM, shows promising tumor regression in preclinical studies and aims for clinical validation to improve patient outcomes.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Preclinical validation and market analysis of a microMESH implant for brain cancer eradicationThe project aims to develop and validate a novel drug delivery implant, microMESH, for targeted chemo-immunotherapy in glioblastoma, enhancing treatment efficacy and patient outcomes. | ERC Proof of... | € 150.000 | 2022 | Details |
Leveraging Polymer Therapeutics as Nanomedicine for Local Glioblastoma ImmunotherapyGLIOMERS aims to develop a brain-penetrating polymeric drug delivery system to enhance immunotherapy efficacy for glioblastoma by localizing treatment and stimulating antitumor immunity. | ERC Starting... | € 1.498.175 | 2025 | Details |
Preclinical in vivo validation of a glioblastoma neuro snooper electrical deviceThis project aims to develop and validate the 'GBM Neuro Snooper' device to improve understanding and treatment of glioblastoma by assessing brain electrophysiology post-tumor resection. | ERC Proof of... | € 150.000 | 2023 | Details |
Trapping and Killing GlioblastomaTrapKill aims to enhance glioblastoma treatment by using a functionalized hydrogel to disrupt DNA repair mechanisms and improve the efficacy of chemo-radiotherapy. | ERC Starting... | € 1.499.938 | 2025 | Details |
RESTORING IMMUNITY CONTROL OF GI CANCERSTIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization. | EIC Transition | € 2.007.750 | 2025 | Details |
Preclinical validation and market analysis of a microMESH implant for brain cancer eradication
The project aims to develop and validate a novel drug delivery implant, microMESH, for targeted chemo-immunotherapy in glioblastoma, enhancing treatment efficacy and patient outcomes.
Leveraging Polymer Therapeutics as Nanomedicine for Local Glioblastoma Immunotherapy
GLIOMERS aims to develop a brain-penetrating polymeric drug delivery system to enhance immunotherapy efficacy for glioblastoma by localizing treatment and stimulating antitumor immunity.
Preclinical in vivo validation of a glioblastoma neuro snooper electrical device
This project aims to develop and validate the 'GBM Neuro Snooper' device to improve understanding and treatment of glioblastoma by assessing brain electrophysiology post-tumor resection.
Trapping and Killing Glioblastoma
TrapKill aims to enhance glioblastoma treatment by using a functionalized hydrogel to disrupt DNA repair mechanisms and improve the efficacy of chemo-radiotherapy.
RESTORING IMMUNITY CONTROL OF GI CANCERS
TIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization.